Navigation Links
Welsh shingles drug set for final hurdle
Date:3/23/2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy together with a virology group at the Rega Institute in Belgium and US biopharmaceutical company, Inhibitex Inc, is due to complete Phase II of its clinical trials.

If the drug completes Phase II it will enter the third and final stage which could see the drug being available to patients in less than three years.

Cardiff University's Professor of Medical Chemistry, Chris McGuigan, who led the team which discovered the new antiviral drug, said: "We are now entering the final and most crucial stage in the journey from the discovery of a new drug to the market.

"If we successfully complete this stage the drug would be available to help alleviate the pain and suffering for millions of shingles patients, not only in Wales but across the world."

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that one-in-five people in the US, Europe and Japan will be affected by the condition during their lifetime.

The condition is characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Initial tests of FV-100 showed it has the potential to greatly reduce all of these symptoms.

In Phase I trials of FV-100, no serious adverse events in healthy volunteers were reported and data supported the potential for once-a-day dosing in future trials.Previous lab research has also shown the drug to be up to 10,000 times more potent against the virus than existing treatments.

Professor McGuigan added: "We believe this drug has the potential to be the most powerful inhibitor ever discovered to treat shingles.

"Each year only 15-20 new medicines are approved for clinical use and the chance of FV100 becoming an approved medicine improves the further we successfully progress through each of the clinical stages.

"We are incredibly excited at the prospect of FV-100 becoming commercially available in the future, and potentially being the first drug discovered in Cardiff University to make it to the marketplace."


'/>"/>

Contact: Chris Jones
JonesC83@cardiff.ac.uk
44-292-087-4731
Cardiff University
Source:Eurekalert

Related medicine news :

1. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
2. Chicken Pox Shot Protects Against Shingles, Too
3. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
4. Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco
5. AKON Fragrance Finally Available at Akonfragrances.com
6. Morehead Associates, Inc. and Child Health Corporation of America (CHCA) Finalize Agreement for Employee and Physician Surveys and Consulting Services
7. Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th
8. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
9. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Kiwanis Selects Three Finalists for Worldwide Service Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Our bodies ... effective way to confront and deal with these stressors is to adopt a more ... be good for you. Risa Groux, a certified Holistic Nutritionist and the creator of ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American ... productivity, stability, even security. Most importantly, employees are the single most important asset ... American workers so unhappy? , Just under half of American workers are emotionally ...
(Date:4/29/2016)... Sterling, VA (PRWEB) , ... April 29, 2016 ... ... Americans with student loans more flexibility in repaying their loans, more information about ... at a time when total outstanding student loan debt, including federal and private ...
(Date:4/29/2016)... ... ... Coast Dental Fort Stewart is celebrating its grand opening with an open ... Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, and ... the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, and ...
(Date:4/29/2016)... Texas (PRWEB) , ... April 29, 2016 , ... Spine ... neck pain, is proud to announce one of their physicians has been invited to ... Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
(Date:4/27/2016)... NEW DELHI , April 27, 2016 ... CSR initiative to save newborns ... ,s hospital for women & newborns in collaboration with Breast ... has launched the first Pasteurized Human Milk Bank, ,Amaara, in ... the best nutritional food source for infants and should be ...
(Date:4/27/2016)... Global  urinalysis market  is ... 2022, according to a new report by Grand ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation is ... accuracy delivered by the new generation urinalysis devices ... instruments and consumables. For instance, the automatic bench-top ...
Breaking Medicine Technology: